Logo image of IRON

DISC MEDICINE INC (IRON) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IRON - US2546041011 - Common Stock

92.24 USD
-1.02 (-1.09%)
Last: 12/8/2025, 8:18:48 PM
92.24 USD
0 (0%)
After Hours: 12/8/2025, 8:18:48 PM
Fundamental Rating

2

IRON gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. IRON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IRON is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IRON has reported negative net income.
In the past year IRON has reported a negative cash flow from operations.
In the past 5 years IRON always reported negative net income.
IRON had a negative operating cash flow in each of the past 5 years.
IRON Yearly Net Income VS EBIT VS OCF VS FCFIRON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

IRON has a better Return On Assets (-28.73%) than 68.55% of its industry peers.
The Return On Equity of IRON (-31.59%) is better than 75.14% of its industry peers.
Industry RankSector Rank
ROA -28.73%
ROE -31.59%
ROIC N/A
ROA(3y)-22.05%
ROA(5y)-23.6%
ROE(3y)-24.43%
ROE(5y)-26.32%
ROIC(3y)N/A
ROIC(5y)N/A
IRON Yearly ROA, ROE, ROICIRON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IRON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IRON Yearly Profit, Operating, Gross MarginsIRON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

IRON has more shares outstanding than it did 1 year ago.
IRON has a worse debt/assets ratio than last year.
IRON Yearly Shares OutstandingIRON Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
IRON Yearly Total Debt VS Total AssetsIRON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

IRON has an Altman-Z score of 36.09. This indicates that IRON is financially healthy and has little risk of bankruptcy at the moment.
IRON has a better Altman-Z score (36.09) than 94.73% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that IRON is not too dependend on debt financing.
IRON has a worse Debt to Equity ratio (0.05) than 60.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 36.09
ROIC/WACCN/A
WACCN/A
IRON Yearly LT Debt VS Equity VS FCFIRON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 23.45 indicates that IRON has no problem at all paying its short term obligations.
IRON has a Current ratio of 23.45. This is amongst the best in the industry. IRON outperforms 96.80% of its industry peers.
A Quick Ratio of 23.45 indicates that IRON has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 23.45, IRON belongs to the best of the industry, outperforming 96.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 23.45
Quick Ratio 23.45
IRON Yearly Current Assets VS Current LiabilitesIRON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

IRON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -36.83%.
EPS 1Y (TTM)-36.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IRON is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.10% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-55.71%
EPS Next 2Y-28.67%
EPS Next 3Y-14.82%
EPS Next 5Y16.1%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IRON Yearly Revenue VS EstimatesIRON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
IRON Yearly EPS VS EstimatesIRON Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IRON. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRON Price Earnings VS Forward Price EarningsIRON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRON Per share dataIRON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

A cheap valuation may be justified as IRON's earnings are expected to decrease with -14.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.67%
EPS Next 3Y-14.82%

More info and screens

0

5. Dividend

5.1 Amount

IRON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DISC MEDICINE INC

NASDAQ:IRON (12/8/2025, 8:18:48 PM)

After market: 92.24 0 (0%)

92.24

-1.02 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners85.58%
Inst Owner Change3.69%
Ins Owners0.41%
Ins Owner Change-12.14%
Market Cap3.48B
Revenue(TTM)N/A
Net Income(TTM)-181.11M
Analysts86.32
Price Target120.53 (30.67%)
Short Float %9.56%
Short Ratio5.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.09%
Min EPS beat(2)-33.61%
Max EPS beat(2)-18.57%
EPS beat(4)2
Avg EPS beat(4)-6.92%
Min EPS beat(4)-33.61%
Max EPS beat(4)12.77%
EPS beat(8)4
Avg EPS beat(8)-2.73%
EPS beat(12)6
Avg EPS beat(12)-8.97%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.5%
PT rev (3m)18.49%
EPS NQ rev (1m)-9.25%
EPS NQ rev (3m)-14.35%
EPS NY rev (1m)-8.62%
EPS NY rev (3m)-8.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.07
P/tB 6.07
EV/EBITDA N/A
EPS(TTM)-5.35
EYN/A
EPS(NY)-6.61
Fwd EYN/A
FCF(TTM)-4.4
FCFYN/A
OCF(TTM)-4.36
OCFYN/A
SpS0
BVpS15.19
TBVpS15.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.73%
ROE -31.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.05%
ROA(5y)-23.6%
ROE(3y)-24.43%
ROE(5y)-26.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 677.61%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.45
Quick Ratio 23.45
Altman-Z 36.09
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)193.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.88%
EPS Next Y-55.71%
EPS Next 2Y-28.67%
EPS Next 3Y-14.82%
EPS Next 5Y16.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-63.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-75.04%
EBIT Next 3Y-14.43%
EBIT Next 5YN/A
FCF growth 1Y-143.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-141.91%
OCF growth 3YN/A
OCF growth 5YN/A

DISC MEDICINE INC / IRON FAQ

Can you provide the ChartMill fundamental rating for DISC MEDICINE INC?

ChartMill assigns a fundamental rating of 2 / 10 to IRON.


Can you provide the valuation status for DISC MEDICINE INC?

ChartMill assigns a valuation rating of 0 / 10 to DISC MEDICINE INC (IRON). This can be considered as Overvalued.


How profitable is DISC MEDICINE INC (IRON) stock?

DISC MEDICINE INC (IRON) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for IRON stock?

The Earnings per Share (EPS) of DISC MEDICINE INC (IRON) is expected to decline by -55.71% in the next year.